Atlas Trials

Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer

Clinical trial NCT06394661 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06394661
Sponsor
Henan Cancer Hospital
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2024-04-28
Primary completion
2025-12-30
Enrollment
109

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.